Browett P J, Nelson J, Tiwari S, Van de Water N S, May S, Palmer S J
Department of Molecular Medicine, University of Auckland School of Medicine, New Zealand.
Bone Marrow Transplant. 1994 Oct;14(4):641-4.
The combination of donor leucocytes, with or without interferon, has produced encouraging responses in patients with haematological relapse following allogeneic BMT for chronic myeloid leukaemia (CML). A 25-year-old male received low-dose interferon-alpha alone for haematological relapse occurring 10 months following an allogeneic BMT for Ph-positive CML. Interferon therapy was complicated by severe GVHD requiring immunosuppressive therapy. The patient was subsequently found to be in complete haematological and cytogenetic remission, raising the possibility of an immune-mediated antileukaemic action.
对于慢性粒细胞白血病（CML）接受异基因骨髓移植（BMT）后出现血液学复发的患者，供体白细胞联合或不联合干扰素治疗已产生了令人鼓舞的反应。一名25岁男性在接受Ph阳性CML异基因BMT后10个月出现血液学复发，单独接受了低剂量α干扰素治疗。干扰素治疗因严重移植物抗宿主病（GVHD）而复杂化，需要进行免疫抑制治疗。该患者随后被发现处于完全血液学和细胞遗传学缓解状态，这增加了免疫介导的抗白血病作用的可能性。
